Probability of anti-D development in D- patients receiving D+ RBCs.
about
The Influence of Clinical and Biological Factors on Transfusion-Associated Non-ABO Antigen Alloimmunization: Responders, Hyper-Responders, and Non-RespondersRHD PCR of D-Negative Blood DonorsApplication of a Multivariant, Caucasian-Specific, Genotyped Donor Panel for Performance Validation of MDmulticard®, ID-System®, and Scangel® RhD/ABO Serotyping.Responder individuality in red blood cell alloimmunization.Low frequency of anti-D alloimmunization following D+ platelet transfusion: the Anti-D Alloimmunization after D-incompatible Platelet Transfusions (ADAPT) studyTransfusion in the absence of inflammation induces antigen-specific tolerance to murine RBCs.Rhesus Negative Woman Transfused With Rhesus Positive Blood: Subsequent Normal Pregnancy Without Anti D production.Rh complexities: serology and DNA genotyping.Red blood cell transfusion risks in patients with end-stage renal disease.Platelet transfusion - the art and science of compromiseDetermination of the frequency of the most immunogenic Rhesus antigens among Saudi donors in King Abdulaziz Medical City - Riyadh.Variants of RhD--current testing and clinical consequences.Red cell transfusion and the immune system.A case for stocking O D+ red blood cells in emergency room trauma bays.Weak D types in the Egyptian population.Low incidence of D alloimmunization among patients with a serologic weak D phenotype after D+ transfusion.Cancer type predicts alloimmunization following RhD-incompatible RBC transfusions.Prevalence of Rh, Duffy, Kell, Kidd & MNSs blood group antigens in the Indian blood donor populationPrevalence of RhD variants among blood donors at Gulu Regional Blood Bank, Gulu, Northern Uganda.Minor RBC Ab and allo-SCT.Intensive red blood cell transfusions and risk of alloimmunization.Obstetric and trauma database review at a single institution finds the optimal maternal age restriction for the transfusion of O- blood to women involved in trauma to be 45 years.Frequency and prognostic value of D alloantibodies after D-mismatched allogeneic hematopoietic stem cell transplantation after reduced-intensity conditioning.How do I implement a whole blood program for massively bleeding patients?Application of the ADVIA cerebrospinal fluid assay to count residual red blood cells in blood components.Anti-D investigations in individuals expressing weak D Type 1 or weak D Type 2: allo- or autoantibodies?Rh and Kell Phenotype Matched Blood Versus Randomly Selected and Conventionally Cross Matched Blood on Incidence of Alloimmunization.Does an alloimmune response to strong immunogenic red blood cell antigens enhance a response to weaker antigens?Detection of anti-D in D- recipients transfused with D+ red blood cells.Recipient inflammation affects the frequency and magnitude of immunization to transfused red blood cells.Unmatched Type O RhD+ Red Blood Cells in Multiple Injured Patients.
P2860
Q27000807-C3ACA5F1-762D-494B-A432-E183F7FE1761Q28672928-32BB0324-63BF-47C3-BAC1-4CDEAE619C11Q34306093-B4C3B274-28E8-4A36-A2AE-2BD8315CE43CQ34791984-04EE7AB2-C4D5-4217-857E-6DCCC21C69D2Q35040235-CD6AB5FA-0A8B-4D4E-AF5F-02230EDFC8ADQ35776447-642BAACE-090B-4D13-8E98-F0047191A221Q35996789-20B8164D-7FAC-4620-8D06-D5F0DB2F38C9Q36861110-23CF5B53-328A-4499-8C63-5D5DDFF4D07AQ36913888-64799611-1AC4-49A4-B011-22864C5076ADQ37049262-1D93288A-6CC4-450C-98E3-BE0FAA87B1C1Q37658597-B8A58AD9-5075-44A9-8BDE-C37308F95DE5Q38083742-DB31CC09-8138-40A4-9D79-1FA82FCEAB3DQ38273784-21234A02-9881-4F38-8602-F7AF5EB786D0Q38274650-817DDC15-BD55-4323-9F8C-5D74412021B7Q39089407-9DC74252-B802-4DB3-B298-C84FCE4A6E85Q39613099-86908422-C9E2-4ACA-BC92-4F0660CE539DQ40338666-EE4436A1-9098-4C26-BA5D-F1090A94A3DEQ41878443-83F4803F-B88F-4CED-9279-1388C60EDE8FQ42362065-BEC67696-6AB4-4017-8CC0-C996411355EBQ43618201-4BE4CE2A-9FB9-4CD2-90D9-365B878CEDE3Q44088536-6F2FB0F7-CF6B-4703-8551-34A56824FB0FQ45165450-14A59B81-E7BD-463B-8B10-07F4A782D019Q45172618-F617C63E-169D-448B-AA41-F6C304A69169Q50052955-87E28AE8-07B7-4C58-9E6D-9B9A7BAB2764Q50514989-01816662-7565-4CD9-B0B2-314DD02793B9Q50533012-0AB52C29-42F7-4DB6-9C6E-11BBF8D3B6E6Q50594154-4BC02E37-9027-4E35-B7C7-2E77C2D7CFBFQ50650747-DCF6D002-471E-4EA5-84F6-3305C6BBEF0BQ50682132-4774BE73-513C-4C14-A5A8-7D48551AAC02Q50721622-77DD2439-9573-49BB-8A41-95D41BBDC294Q55339310-F136FCA0-0321-4749-85D6-FCF5AD405C92
P2860
Probability of anti-D development in D- patients receiving D+ RBCs.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
2003年學術文章
@zh-hant
name
Probability of anti-D development in D- patients receiving D+ RBCs.
@en
Probability of anti-D development in D- patients receiving D+ RBCs.
@nl
type
label
Probability of anti-D development in D- patients receiving D+ RBCs.
@en
Probability of anti-D development in D- patients receiving D+ RBCs.
@nl
prefLabel
Probability of anti-D development in D- patients receiving D+ RBCs.
@en
Probability of anti-D development in D- patients receiving D+ RBCs.
@nl
P2093
P1433
P1476
Probability of anti-D development in D- patients receiving D+ RBCs.
@en
P2093
Christoph Frohn
Holger Kirchner
Jörg-Matthias Brand
Jürgen Luhm
Lutz Dümbgen
Siegfried Görg
P2860
P304
P356
10.1046/J.1537-2995.2003.00394.X
P577
2003-07-01T00:00:00Z